Lucinactant is a new synthetic peptide-containing surfactant for intratracheal use. It contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human surfactant protein-B (SB-P). More specifically, it mimics the C-terminal amphipathic helical domain of this protein. It also consists of phospholipids (dipalmitoylphosphatidylcholine, DPPC and palmitoyloleoyl phosphatidylglycerol, POPG) and a fatty acid (palmitic acid). It is completely devoid of animal-derived components.
CAT No: 10-101-168
CAS No:138531-07-4
Synonyms/Alias:Sinapultide;138531-07-4;Kl4 peptide;ATI 01;KL4 (peptide);Sinapultida;Sinapultide [USAN:INN];UNII-040X3AX99T;PEPTIDE KL4;PEPTIDE KL-4;RWJ 45652;ATI-01;DTXSID30160707;040X3AX99T;RWJ-45652;SINAPULTIDE (MART.);SINAPULTIDE [MART.];L-Lysine, L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-;L-Lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysine;Sinapultidum;SINAPULTIDE [MI];SINAPULTIDE [INN];SINAPULTIDE [USAN];SCHEMBL180504;CHEMBL2103901;DTXCID3083198;AT42478;DB11332;DA-67594;NS00124788;
KL4, a 21-residue peptide containing repeating KLLLL subunits, represents one of the early synthetic surfactant peptides designed to roughly reflect the overall ratio of cationic to hydrophobic amino acids found in native SP-B (22). Despite an early demonstration of SP-B-like activity and the fact that KL4 is currently under evaluation for FDA approval for clinical use as the peptide component of the synthetic exogenous surfactant Surfaxin (Lucinactant), surprisingly little is known about the specific effects of KL4 on phospholipid interfacial film behavior during compression/expansion and collapse.
KL4 Peptide Induces Reversible Collapse Structures on Multiple Length Scales in Model Lung Surfactant
KL4 ([lysine-(leucine)4]4-lysine) is a synthetic peptide based on SP-B structure and is the major constituent of Surfaxin®, a potential therapeutic agent for respiratory distress syndrome in premature infants. There is, however, no clear understanding about the possible lipid-KL4 interactions behind its function, which is an inevitable knowledge to design improved therapeutic agents. To examine the phase behavior, topography, and lipid specificity of KL4/lipid systems, we aimed to study different surfactant model systems containing KL4, neutral dipalmitoylphosphatidylcholine (DPPC) and/or negatively charged dipalmitoylphosphatidylglycerol (DPPG) in the presence of Ca2+ ions. Surface pressure-area isotherms, fluorescence microscopic images, scanning force microscopy as well as time-of-flight secondary ion mass spectrometry suggest that KL4 is not miscible with DPPC and therefore forms peptide aggregates in DPPC/KL4 mixtures; that KL4 specifically interacts with DPPG via electrostatic interactions and induces percolation of DPPG-rich phases; that existing DPPG-Ca2+ interactions are too strong to be overcome by KL4, the reason why the peptide remains excluded from condensed DPPG domains and passively colocalizes with DPPC in a demixed fluid phase; and that the presence of negatively charged lipid is necessary for the formation of bilayer protrusions. These results indicate that the capability of the peptide to induce the formation of a defined surface-confined reservoir depends on the lipid environment, especially on the presence of anionic lipids.
The Surfactant Peptide KL4 in Lipid Monolayers
1. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
3. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists
4. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More